

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5883876
<b>Application Number:</b>	10786907
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6743
<b>Title of Invention:</b>	Modified antibody
<b>First Named Inventor/Applicant Name:</b>	Bjarne Bogen
<b>Customer Number:</b>	27572
<b>Filer:</b>	Fernando Alberdi/Andrea Blendea
<b>Filer Authorized By:</b>	Fernando Alberdi
<b>Attorney Docket Number:</b>	36731S-000001/US
<b>Receipt Date:</b>	13-AUG-2009
<b>Filing Date:</b>	25-FEB-2004
<b>Time Stamp:</b>	15:12:49
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$470
RAM confirmation Number	1299
Deposit Account	080750
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment Submitted/Entered with Filing of CPA/RCE	Amendment_After_Final_and_RCE.PDF	1424367	no	20
			8bf6f3d6eddb4ca40abe739e124c40611ed68d6		

### Warnings:

### Information:

2	Extension of Time	Petition_For_Ext_of_Time.PDF	118476	no	1
			03e3320c93b38595d19c25e022f901862ad340d8		

### Warnings:

### Information:

3	Request for Continued Examination (RCE)	RCE.PDF	154182	no	1
			60aff569ab75edabace7e41a1dbfcbec18ff513a		

### Warnings:

This is not a USPTO supplied RCE SB30 form.

### Information:

4	Transmittal Letter	IDS.PDF	479682	no	5
			8e1c7b1e93e44a2550122db3e64d4e627f5aeab		

### Warnings:

### Information:

5	NPL Documents	Biragyn_et_al_Genetic_Fusion_of_Chemokines_1999.PDF	863536	no	6
			18604932d3b715e28f539f6a8b95a170a14ed510		

### Warnings:

### Information:

6	NPL Documents	Pluckthun_et_al_New_Protein_Engineering.PDF	1835777	no	23
			78ecee50e5edc530da13516e4d77c3c7a0686870		

### Warnings:

### Information:

7	NPL Documents	Chen_et_al_Linkage_of_CD40L_2002.PDF	888574	no	8
			005b6bbc909779841be4bb487ab49cd844b4f936		

### Warnings:

### Information:

8	NPL Documents	Huang_et_al_Improved_Immuno- nogenicity_2004.PDF	883103	no	8
			101b5b1f9dd7e1962f7483e5f19ec0545d36d760		
Warnings:					
Information:					
9	NPL Documents	Huang_et_al_Enhanced_Anti- mor_Immunity_2000.PDF	940507	no	8
			981f4e541e6bea97fe32843a4ee255dddec116cb		
Warnings:					
Information:					
10	NPL Documents	Kriangkum_et_al_Bispecific_and d_Bifunctional_2001.PDF	1260111	no	10
			08b99389aff144a444982fb1be82bfe0e14cef52		
Warnings:					
Information:					
11	NPL Documents	Van_Spriel_et_al_Immunother- apeutic_Perspective_2000.PDF	965536	no	6
			740baaa977f6da41c0d1452af2047be3ee01595b		
Warnings:					
Information:					
12	NPL Documents	Hoogenboom_Mix_and_Match _1997.PDF	335777	no	2
			41de94757f0f85327f364abaf0540e2d42d8c4ba		
Warnings:					
Information:					
13	NPL Documents	HU_et_al_Minibody_1996.PDF	975768	no	7
			214ca351d78443d896915a368b4e4195c79399bb		
Warnings:					
Information:					
14	NPL Documents	Biragyn_et_al_Toll_Like_Recep- tor_2002.PDF	680137	no	5
			61702b7f86ff6df2ce54399f0ab5bfe33446e925		
Warnings:					
Information:					
15	NPL Documents	Lunde_et_al_Troybodies_and_ Pepbodies_2002.PDF	582003	no	7
			f36a358f9b5d9a32704cbef836b5f32c6505b6c0		
Warnings:					
Information:					
16	NPL Documents	Lunde_et_al_Troy_Bodies_Rec- ombinant_Antibodies_2001. PDF	1390696	no	14
			c7fc63726c5940b65b7e2eb956ffc7c8a415a7eb		
Warnings:					
Information:					

17	1.501 Submission by Patent Owner	Ruffini_et_al_Idiotypic_Vaccination_2002.PDF	1652311 47b96a0fa3fbcef1b22c22ad548c05ea20efed39	no	13
<b>Warnings:</b>					
<b>Information:</b>					
18	Information Disclosure Statement (IDS) Filed (SB/08)	Form_1449.PDF	69956 cdf7785d6f502c14c5512401d53f15a49fc03fc2	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
19	Fee Worksheet (PTO-875)	fee-info.pdf	31848 89df38ce8661f93aad0593684651f961f8866a40	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			15532347		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					